Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Glenda Gray
University of the Witswatersrand
Study Chair - Kenneth Mayer
Fenway Community Health
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Soweto Hvtn Crs
Johannesburg, Gauteng, South Africa
- Emavundleni Crs
Cape Town, Western Cape, South Africa
- Brigham and Women'S Hospital Vaccine Crs (bwh Vcrs)
Boston, Massachusetts, United States
- Fenway Health (fh) Crs
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2008
- Primary completion
- 31 Oct 2010
- Completion
- 31 Jan 2013
- Last update posted
- 14 Oct 2021
- Registered enrollment
- 48
- Registry id
- NCT00574600
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.